Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27981979 | 0.85 | PDE4D (0.47) | HPGDCYP3A4PDE4DNFKB1NFKB2 | |
| SCHEMBL10910390 | 0.82 | CTSB (0.46) | HPGDCTSBCCR5PDE4DCTSL | |
| SCHEMBL10908300 | 0.78 | PLA2G2A (0.53) | MEN1KMT2ACTSBCTSLPTPN1 | |
| SCHEMBL12599530 | 0.78 | CTSB (0.58) | HPGDMEN1CYP3A4KMT2ACTSB | |
| SCHEMBL12599523 | 0.73 | HPGD (0.38) | HPGDMEN1CYP3A4KMT2ALMNA | |
| SCHEMBL969014 | 0.69 | CCR5 (0.43) | HPGDCYP3A4CTSBCCR5LMNA | |
| SCHEMBL2484255 | 0.67 | ALOX5 (0.48) | HPGDCYP3A4CCR5PDE4DMALT1 | |
| SCHEMBL7110948 | 0.66 | MEN1 (0.34) | HPGDMEN1CYP3A4KMT2ATHRB | |
| SCHEMBL3246245 | 0.66 | ALDH1A1 (0.49) | CTSBPDE4DCTSLMALT1 | |
| SCHEMBL31545960 | 0.66 | ALDH1A1 (0.49) | CTSBPDE4DCTSLMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586768-B2 | Design, synthesis and functional characterization of rottlerin analogs | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110112182-A1 | DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112182-A1 | DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112182-A1 | DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS | PRKCH, PRKCB, PRKCA | HPGD 1615/4885MEN1 3087/4885CYP3A4 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.